ArticleBMC cancer2026
Integrin-binding sialoprotein as an extracellular matrix-associated independent prognostic biomarker in glioma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIntegrin-binding sialoprotein (IBSP) has been implicated in bone metastasis in breast, lung, and prostate cancers. However, its role in glioma remains insufficiently characterized. The aim of this study was to assess the expression profile and prognostic significance of IBSP in patients with glioma.
methodsGene expression data associated with glioma prognosis were obtained from the Chinese Glioma Genome Atlas and Gene Expression Omnibus Series databases and analyzed in relation to clinical characteristics. The prognostic value of IBSP was assessed using univariate and multivariate Cox regression analyses. Immunohistochemical analysis was performed to validate these findings. Gene set enrichment analysis (GSEA) was conducted to identify molecular pathways associated with IBSP expression and its contribution to adverse prognosis. Additionally, gene set cancer analysis was used to explore potential therapeutic agents targeting IBSP.
resultsIBSP expression was elevated in glioma tissues and demonstrated a positive correlation with increasing World Health Organization grade. Multivariate Cox regression analysis identified IBSP as an independent prognostic factor across multiple datasets (HR = 1.531; 95% CI: 1.07-2.192; p = 0.020). GSEA indicated that IBSP is involved in apoptosis, coagulation, and complement pathways. Several genes, including CASP4, KYNU, MSR1, PLAUR, SIGLEC9, and SLC16A3, were positively correlated with IBSP expression and are implicated in glioma pathogenesis. Furthermore, alvocidib and dinaciclib were identified as potential therapeutic agents targeting IBSP.
conclusionsIBSP represents an independent prognostic biomarker associated with adverse outcomes in glioma. These findings provide insight into the molecular mechanisms underlying IBSP-associated glioma progression and highlight potential therapeutic targets that may contribute to improved clinical outcomes in patients with glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.